On September 3, 2020 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020 (Press release, CohBar, SEP 3, 2020, View Source [SID1234564419]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Annual Global Investment Conference
Tuesday, September 15 at 4:00 PM ET
Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: View Source

On September 3, 2020 TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9th, at 10:40 am EDT (Press release, Tracon Pharmaceuticals, SEP 3, 2020, View Source [SID1234564418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com.

On September 3, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will participate in a fireside chat during the virtual Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 3:30 p.m. Eastern Time (Press release, Seattle Genetics, SEP 3, 2020, View Source [SID1234564416]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT (Press release, Bio-Techne, SEP 3, 2020, View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" target="_blank" title="View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" rel="nofollow">View Source [SID1234564415]). A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link (webcast).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET (Press release, Taiwan Liposome Company, SEP 3, 2020, View Source [SID1234564414]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 30-minute fireside chat will include a company overview followed by a Q&A session. During the conference, which is taking place virtually September 9-10, 2020, TLC will also be participating in one-on-one sessions. While the fireside chat is only accessible to Baird clients registered for the event, a corporate presentation entailing the updates will be available on the company’s website at www.tlcbio.com under the Investors section.